Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rong Sheng

Showing results (431-440 of 436) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 436 results.
Cancer|June 23, 2017
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trialFeng-Hua Wang, Yun Wang, Guo-Ping Sun, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|May 13, 2004
Changed clinical aspects of primary liver cancer in China during the past 30 yearsBing-Hui Yang, Jing-Lin Xia, Li-Wen Huang, et al.
Zhonghua Yi Xue Za Zhi|August 6, 2003
[Changes of clinical aspect of primary liver cancer in China during the past 30 years--control study for 3,250 cases with primary liver cancer]Bing-hui Yang, Jing-lin Xia, Li-wen Huang, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Angewandte Chemie (International Ed. in English)|January 27, 2024
Engineering Hydroxylase Activity, Selectivity, and Stability for a Scalable Concise Synthesis of a Key Intermediate to BelzutifanWai Ling Cheung-Lee, Joshua N Kolev, John A McIntosh, et al.
Pageof 44

Showing results (431-440 of 436) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 436 results.
Cancer|June 23, 2017
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trialFeng-Hua Wang, Yun Wang, Guo-Ping Sun, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|May 13, 2004
Changed clinical aspects of primary liver cancer in China during the past 30 yearsBing-Hui Yang, Jing-Lin Xia, Li-Wen Huang, et al.
Zhonghua Yi Xue Za Zhi|August 6, 2003
[Changes of clinical aspect of primary liver cancer in China during the past 30 years--control study for 3,250 cases with primary liver cancer]Bing-hui Yang, Jing-lin Xia, Li-wen Huang, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Angewandte Chemie (International Ed. in English)|January 27, 2024
Engineering Hydroxylase Activity, Selectivity, and Stability for a Scalable Concise Synthesis of a Key Intermediate to BelzutifanWai Ling Cheung-Lee, Joshua N Kolev, John A McIntosh, et al.
Pageof 44